CTOR
Citius Oncology, Inc.NASDAQHealthcare$0.70+8.47%ClosedMarket Cap: $62.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.03
P/S
15.38
EV/EBITDA
-2.63
DCF Value
$0.11
FCF Yield
-21.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.0%
Operating Margin
-567.4%
Net Margin
-599.3%
ROE
-55.2%
ROA
-21.5%
ROIC
-34.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 2026 | $3.9M | 80.0% | $-5.3M | $-5.5M | $-0.06 | — |
| Q4 2025 | $0.00 | NaN% | $-4.7M | $-5.0M | $-0.06 | — |
| FY 2025 | $0.00 | NaN% | $-23.5M | $-24.8M | $-0.34 | — |
| Q3 2025 | $0.00 | NaN% | $-4.9M | $-5.4M | $-0.08 | — |
| Q2 2025 | $0.00 | NaN% | $-7.5M | $-7.7M | $-0.11 | — |
| Q1 2025 | $0.00 | NaN% | $-6.4M | $-6.7M | $-0.09 | — |
| Q4 2024 | $0.00 | NaN% | $-6.7M | $-6.8M | $-0.10 | — |
| FY 2024 | $0.00 | NaN% | $-20.6M | $-21.1M | $-0.30 | — |
| Q3 2024 | $0.00 | NaN% | $-4.6M | $-4.8M | $-0.07 | — |
| Q2 2024 | $0.00 | NaN% | $-4.7M | $-4.8M | $-0.07 | — |
| Q1 2024 | $0.00 | NaN% | $-4.6M | $-4.7M | $-0.06 | — |
| Q4 2023 | $0.00 | NaN% | $-5.0M | $-5.2M | $-0.37 | — |